Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-sequence Study to Investigate the Effects of BMS-986165 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil (MMF) in Healthy Male Subjects

Trial Profile

An Open-label, Single-sequence Study to Investigate the Effects of BMS-986165 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil (MMF) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs BMS 986165 (Primary) ; Mycophenolate mofetil
  • Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 27 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 05 Nov 2018 Planned End Date changed from 2 Oct 2018 to 6 Nov 2018.
    • 05 Nov 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top